It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders

This paper describes the burden of receiving immunoglobulin (Ig) treatment from the perspective of patients diagnosed with a Primary Immunodeficiency (PID). Thirty semi-structured interviews with patients receiving intravenous (n=21) and subcutaneous immunoglobulin (n=9) therapy, either at home or...

Full description

Bibliographic Details
Main Authors: Georgina Jones, Eva Brown Hajdukova, Esmee Hanna, Rosie Duncan, Brendan Gough, Jane Hughes, Debbie Hughes, Fran Ashworth, Johan Prevot, Jose Drabwell, Leire Solis, Nizar Mahlaoui, Anna Shrimpton
Format: Article
Language:English
Published: PAGEPress Publications 2021-02-01
Series:Qualitative Research in Medicine & Healthcare
Subjects:
Online Access:https://pagepressjournals.org/index.php/qrmh/article/view/9564
id doaj-db51ca79a1bc4f59b3660e34d70a89dc
record_format Article
spelling doaj-db51ca79a1bc4f59b3660e34d70a89dc2021-02-25T21:09:09ZengPAGEPress PublicationsQualitative Research in Medicine & Healthcare2532-20442021-02-014310.4081/qrmh.2020.9564It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disordersGeorgina Jones0Eva Brown Hajdukova 1Esmee Hanna2Rosie Duncan3Brendan Gough4Jane Hughes5Debbie Hughes6Fran Ashworth7Johan Prevot8Jose Drabwell9Leire Solis10Nizar Mahlaoui11Anna Shrimpton12Department of Psychology, School of Social Sciences, Leeds Beckett University, LeedsParexel Access Consulting, Parexel International, LondonCentre for Health Promotion School of Health and Community Studies, De Montfort University, LeicesterSchool of Health and Related Research, University of Sheffield, SheffieldDepartment of Psychology, School of Social Sciences, Leeds Beckett University, LeedsSchool of Health and Related Research, University of Sheffield, SheffieldClinical Immunology and Allergy Unit, Northern General Hospital, Sheffield Teaching Hospitals and NHS Foundation Trust, SheffieldClinical Immunology and Allergy Unit, Northern General Hospital, Sheffield Teaching Hospitals and NHS Foundation Trust, SheffieldInternational Patient Organisation for Primary Immunodeficiencies, Rocky Bottom, Trerieve, Downderry, CornwallInternational Patient Organisation for Primary Immunodeficiencies, Rocky Bottom, Trerieve, Downderry, CornwallInternational Patient Organisation for Primary Immunodeficiencies, Rocky Bottom, Trerieve, Downderry, CornwallFrench National Reference Center for Primary Immune Deficiencies (CEREDIH), Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Pediatric Immuno-Haematology and Rheumatology Unit, Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, ParisClinical Immunology and Allergy Unit, Northern General Hospital, Sheffield Teaching Hospitals and NHS Foundation Trust, Sheffield This paper describes the burden of receiving immunoglobulin (Ig) treatment from the perspective of patients diagnosed with a Primary Immunodeficiency (PID). Thirty semi-structured interviews with patients receiving intravenous (n=21) and subcutaneous immunoglobulin (n=9) therapy, either at home or in hospital were undertaken. Underpinned by a phenomenological theoretical framework, and using a qualitative, inductive thematic approach to prioritise patients’ concerns, we identified that Ig treatment requires considerable effort by the patient, particularly in relation to the amount of time, organization and planning that is needed. They also face numerous physical, social, relationship, emotional, role functioning, travelling, and financial challenges in their effort to undergo and maintain their infusions and care for their health. Some qualitative differences in treatment burden were noted between home and hospital settings which contributed to non-adherence to those regimes. Immunoglobulin treatment burden is complex and influenced by therapeutic mode and setting and the personal circumstances of the patient. As choice over treatment method appears to be mainly informed by lifestyle needs, PID patients may benefit from more information about these potential Ig lifestyle influences when selecting which form of treatment to take together with their health professional. https://pagepressjournals.org/index.php/qrmh/article/view/9564Primary immunodeficiencyimmunoglobulin treatmentqualitative researchthematic analysis
collection DOAJ
language English
format Article
sources DOAJ
author Georgina Jones
Eva Brown Hajdukova
Esmee Hanna
Rosie Duncan
Brendan Gough
Jane Hughes
Debbie Hughes
Fran Ashworth
Johan Prevot
Jose Drabwell
Leire Solis
Nizar Mahlaoui
Anna Shrimpton
spellingShingle Georgina Jones
Eva Brown Hajdukova
Esmee Hanna
Rosie Duncan
Brendan Gough
Jane Hughes
Debbie Hughes
Fran Ashworth
Johan Prevot
Jose Drabwell
Leire Solis
Nizar Mahlaoui
Anna Shrimpton
It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders
Qualitative Research in Medicine & Healthcare
Primary immunodeficiency
immunoglobulin treatment
qualitative research
thematic analysis
author_facet Georgina Jones
Eva Brown Hajdukova
Esmee Hanna
Rosie Duncan
Brendan Gough
Jane Hughes
Debbie Hughes
Fran Ashworth
Johan Prevot
Jose Drabwell
Leire Solis
Nizar Mahlaoui
Anna Shrimpton
author_sort Georgina Jones
title It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders
title_short It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders
title_full It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders
title_fullStr It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders
title_full_unstemmed It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders
title_sort it’s long-term, well it’s for life basically: understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders
publisher PAGEPress Publications
series Qualitative Research in Medicine & Healthcare
issn 2532-2044
publishDate 2021-02-01
description This paper describes the burden of receiving immunoglobulin (Ig) treatment from the perspective of patients diagnosed with a Primary Immunodeficiency (PID). Thirty semi-structured interviews with patients receiving intravenous (n=21) and subcutaneous immunoglobulin (n=9) therapy, either at home or in hospital were undertaken. Underpinned by a phenomenological theoretical framework, and using a qualitative, inductive thematic approach to prioritise patients’ concerns, we identified that Ig treatment requires considerable effort by the patient, particularly in relation to the amount of time, organization and planning that is needed. They also face numerous physical, social, relationship, emotional, role functioning, travelling, and financial challenges in their effort to undergo and maintain their infusions and care for their health. Some qualitative differences in treatment burden were noted between home and hospital settings which contributed to non-adherence to those regimes. Immunoglobulin treatment burden is complex and influenced by therapeutic mode and setting and the personal circumstances of the patient. As choice over treatment method appears to be mainly informed by lifestyle needs, PID patients may benefit from more information about these potential Ig lifestyle influences when selecting which form of treatment to take together with their health professional.
topic Primary immunodeficiency
immunoglobulin treatment
qualitative research
thematic analysis
url https://pagepressjournals.org/index.php/qrmh/article/view/9564
work_keys_str_mv AT georginajones itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT evabrownhajdukova itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT esmeehanna itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT rosieduncan itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT brendangough itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT janehughes itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT debbiehughes itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT franashworth itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT johanprevot itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT josedrabwell itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT leiresolis itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT nizarmahlaoui itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
AT annashrimpton itslongtermwellitsforlifebasicallyunderstandingandexploringtheburdenofimmunoglobulintreatmentinpatientswithprimaryimmunodeficiencydisorders
_version_ 1724251012889313280